The association of FGF23 levels in obese adolescents with insulin sensitivity

Wójcik, Małgorzata; Januś, Dominika; Doleżal-Ołtarzewska, Katarzyna; Drożdż, Dorota; Sztefko, Krystyna; Starzyk, Jerzy

doi:10.1515/jpem-2012-0064

Cited by 41 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have pointed to the potential role of the FGF23 in the development of insulin resistance and its metabolic consequences. Previous research by the authos of the current has shown that FGF23 may play a key role in the early phase of decreased insulin sensitivity in obese adolescents [15,16].…”

Section: Discussionmentioning

confidence: 78%

The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents – Preliminary results

Wójcik

Januś

Kalicka-Kasperczyk

et al. 2017

Ann Agric Environ Med.

Self Cite

View full text Add to dashboard Cite

Introduction and objective. Vitamin D deficiency is common in obesity; however, its contribution in the development of metabolic complications remains uncertain. The aim of the study was to examine the relationships between vitamin D status and metabolic complications. Materials and method. The results of blood pressure measurements, biochemical tests and ultrasound of the liver were compared in both groups. The study was conducted at the Children's University Hospital in Krakow, Poland. 30 obese adolescents (mean 13.23y.o.); 18 with 25OHD levels <20ng/mL, 12 with 25OHD>20 ng/mL. Results. The vitamin D deficient group presented with significantly higher values of the diastolic blood pressure (125.9vs.115mmHg), uric acid level (384.7vs.301.5umol/L) and lower phosphorus level (1.4vs.1.65mmol/L), higher prevalence of arterial hypertension (44vs.8.3%), and liver steatosis (25vs.8.3%); lower, but not significantly, levels of fibroblast growth factor 23 and fibroblast growth factor 19. Conclusions. Hypovitaminosis D in obese adolescents is associated with higher prevalence of arterial hypertension, liver steatosis, elevated serum uric acid and low phosphorus levels. The potential contribution of the fibroblast growth factor 23 and fibroblast growth factor 19 in these complications development needs further investigation.

show abstract

Section: Discussionmentioning

confidence: 78%

The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents – Preliminary results

Wójcik

Januś

Kalicka-Kasperczyk

et al. 2017

Ann Agric Environ Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is time to think beyond the realms of traditional liver-muscle-pancreas-adipose tetrad and consider other facets of the metabolic world. It is possible that PTH status is only one piece of the vitamin D-glucose-insulin puzzle, and other players, such as the newly discovered fibroblast growth factor 23 (19) and bone morphogenic proteins (20), also could exert modulatory effects on individuals with given vitamin D and PTH status. …”

mentioning

confidence: 99%

PTH-Vitamin D-Glycemia Interactions Reloaded

Lee

2014

Diabetes

View full text Add to dashboard Cite

“…Wojcik and cols. observed an inverse correlation between FGF23 levels and HOMA-IR in obese adolescents (37). Holecki and cols.…”

Section: Resultsmentioning

confidence: 89%

Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?

Kızılgül

Kan

Beysel

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: This study was designed to compare the serum levels of fibroblast growth factor 23 (FGF23) among patients with gestational diabetes mellitus (GDM) and healthy pregnant women, and to evaluate the association between hormonal and metabolic parameters. Subjects and methods: A total of 82 pregnant women were consecutively enrolled in the study. Of these, 46 were diagnosed as having GDM; the remaining 36 healthy pregnant women served as controls in a cross-sectional study design. The womens' ages ranged from 22 to 38 years and gestational ages, from 24 to 28 weeks. Serum samples were analyzed for FGF23 levels using an enzyme-linked immunosorbent assay. Results: Serum FGF23 levels were increased in patients with GDM compared with controls (median, 65.3 for patients with GDM vs. 36.6 ng/mL for healthy controls; p = 0.019). Mean fasting glucose (105.6 ± 7.4 vs. 70.2 ± 7.2 mg/dL, p < 0.001), HbA1c (5.6 ± 0.5 vs. 4.9 ± 0.5%, p < 0.001), insulin (median, 11.1 vs. 8.7 µIU/mL, p = 0.006) and HOMA-IR (3.0 (1.8) vs 1.4 (0.6), p < 0.001) levels were significantly higher in patients with GDM than in controls. Serum FGF23 level was positively correlated with body mass index (r 2 = 0.346, p < 0.05), FPG (r 2 = 0.264, p < 0.05), insulin (r 2 = 0.388, p < 0.05), HOMA-IR (r 2 = 0.384, p < 0.05). Conclusion: Serum FGF23 levels were higher in women with GDM compared with controls. The present findings suggest that FGF23 could be a useful marker of cardiovascular disease in GDM.

show abstract

The association of FGF23 levels in obese adolescents with insulin sensitivity

Abstract: In adolescents with simple obesity and insulin resistance, FGF23 levels are lower compared with obese adolescents with normal HOMA-IR.

Cited by 41 publications

References 0 publications

The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents – Preliminary results

The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents – Preliminary results

PTH-Vitamin D-Glycemia Interactions Reloaded

Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?

Contact Info

Product

Resources

About